These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34899193)

  • 21. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
    Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
    Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orphan GPR52 as an emerging neurotherapeutic target.
    Ali S; Wang P; Murphy RE; Allen JA; Zhou J
    Drug Discov Today; 2024 Apr; 29(4):103922. PubMed ID: 38387741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.
    Kotowska-Zimmer A; Przybyl L; Pewinska M; Suszynska-Zajczyk J; Wronka D; Figiel M; Olejniczak M
    Mol Ther Nucleic Acids; 2022 Jun; 28():702-715. PubMed ID: 35664700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
    Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
    J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
    Hu J; Matsui M; Corey DR
    Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Strategies to Target Protein Aggregation in Huntington's Disease.
    Jarosińska OD; Rüdiger SGD
    Front Mol Biosci; 2021; 8():769184. PubMed ID: 34869596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Advances for Huntington's Disease.
    Kumar A; Kumar V; Singh K; Kumar S; Kim YS; Lee YM; Kim JJ
    Brain Sci; 2020 Jan; 10(1):. PubMed ID: 31940909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regenerative Approaches in Huntington's Disease: From Mechanistic Insights to Therapeutic Protocols.
    Sassone J; Papadimitriou E; Thomaidou D
    Front Neurosci; 2018; 12():800. PubMed ID: 30450032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
    Dufour BD; Smith CA; Clark RL; Walker TR; McBride JL
    Mol Ther; 2014 Apr; 22(4):797-810. PubMed ID: 24390280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and Possible Future Therapeutic Options for Huntington's Disease.
    Ferguson MW; Kennedy CJ; Palpagama TH; Waldvogel HJ; Faull RLM; Kwakowsky A
    J Cent Nerv Syst Dis; 2022; 14():11795735221092517. PubMed ID: 35615642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.
    Dabrowska M; Juzwa W; Krzyzosiak WJ; Olejniczak M
    Front Neurosci; 2018; 12():75. PubMed ID: 29535594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging pharmacological approaches for Huntington's disease.
    Singh K; Jain D; Sethi P; Gupta JK; Tripathi AK; Kumar S; Sarker SD; Nahar L; Guru A
    Eur J Pharmacol; 2024 Oct; 980():176873. PubMed ID: 39117264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
    Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
    PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gene-selective treatment approaches for Huntington's disease].
    Mühlbäck A; Lindenberg KS; Saft C; Priller J; Landwehrmeyer GB
    Nervenarzt; 2020 Apr; 91(4):303-311. PubMed ID: 32179957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.